title: Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
abstract: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal bone marrow disorder which results in the loss of glycosylphosphatidyl inositol (GPI) anchors from cell membranes. As a consequence, membrane inhibitors of complement are lost rendering the cells more susceptible to complement mediated destruction. This results in hemolysis, leukopenia, thrombocytopenia and thrombophilia. Eculizumab, a monoclonal antibody to complement protein 5, has been approved for the treatment of PNH and is associated with a significant reduction in hemolysis, thromboembolic events and fatigue. We prospectively studied the effect of Eculizumab therapy on plasma markers of thrombin generation (D-Dimers, TAT), inflammation (IL-6), soluble P-selectin (sP-selectin), antigenic (TFMP) and functional (fTFMP) tissue factor bearing microparticles and total plasma microparticle ex vivo factor Xa generation (MPFXa) in eleven Eculizumab naive PNH patients. Blood sampling occurred day 1, prior to Eculizumab treatment, then on days 8,15,22,29, 43, 90. Our results demonstrate a statistically significant reduction in D-Dimer, TAT, IL-6, sP-selectin, and TFMP during the induction phase of treatment (day 1-29) which was sustained during the maintenance treatment (day 29-90). Although the serum LDH levels decreased rapidly, there was no correlation between the change in LDH and the markers of thrombin generation and inflammation. Although there was a statistically significant decrease in TFMP, this decrease did not correlate with changes in markers of thrombin generation or inflammation. Ex vivo MPFXa generation did not decrease with Eculizumab treatment suggesting continued microparticle formation despite inhibition of hemolysis. Ex vivo total microparticle FXa generation was found to have an inverse correlation with markers of thrombin generation, suggesting that in PNH patients in vivo thrombin generation occurs by a pathway independent of hemolysis and microparticle generation.
authors.affiliation: Department of Medicine, University of Southern California-Keck School of Medicine, Los Angeles 90033, CA, USA. iweitz@usc.edu
authors.forename: Ilene C
authors.initials: IC
authors.lastname: Weitz
authors.forename: Pedram
authors.initials: P
authors.lastname: Razavi
authors.forename: Leanne
authors.initials: L
authors.lastname: Rochanda
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Zwicker
authors.forename: Bruce
authors.initials: B
authors.lastname: Furie
authors.forename: David
authors.initials: D
authors.lastname: Manly
authors.forename: Nigel
authors.initials: N
authors.lastname: Mackman
authors.forename: Ralph
authors.initials: R
authors.lastname: Green
authors.forename: Howard A
authors.initials: HA
authors.lastname: Liebman
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D055252:Cell-Derived Microparticles / Q000187:drug effects*; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D013917:Thrombin / Q000032:analysis*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; C481642:eculizumab; D013917:Thrombin